Status:
TERMINATED
Symptom Burden in Head and Neck Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Head And Neck Cancer
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this clinical research study is to compare armodafinil, bupropion, and minocycline when given alone or in combination. Researchers want to learn about the safety and level of effectiveness...
Detailed Description
The Study Drugs: It is not known which study drug or combination of study drugs is better at reducing side effects patients may experience during chemoradiation therapy. For this reason, researchers ...
Eligibility Criteria
Inclusion
- Patients with a pathologically proven diagnosis of epithelial carcinoma of the oropharynx, nasopharynx, hypopharynx, larynx, or oral cavity being treated at MDACC.
- Patients \>/= 18 years old and \</= 65 years old.
- Patients with the above cancers scheduled to receive definitive concurrent chemoradiation over 6 - 7 weeks.
- Patients who speak English (due to the novel research and its complexity, we are only accruing English speaking patients to the protocol)
- Patients must agree to discontinue any current herbal supplement use, and refrain from taking any herbal supplement while on protocol.
- Patients must be willing and able to review, understand, and provide written consent.
- Women of childbearing potential (women who are not postmenopausal for at least one year and are not surgically sterile) must have negative urine pregnancy test..
- Sexually active males and females must agree to use birth control or abstinence for the duration of the trial.
Exclusion
- Patients who are taking medications or have conditions that potentially preclude use of any study medications or interventions as determined by the treating physician
- Patients taking CHANTIX (smoking cessation medication)
- Patients who are enrolled in other symptom management trial or receiving active therapy as part of a treatment clinical trial.
- Bile duct obstruction or cholelithiasis
- History of clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reaction
- Pre-existing psychosis or bipolar disorder. Patients with major depressive disorder or severe depression (a score of 13 or greater on the BDI Fast Screen (BDI-FS) will be excluded. If this is the case, we will notify their treating physician for appropriate management or referral.
- Pre-existing renal impairment: The screening cut off for serum creatinine \> the upper limit of normal, will be done by the oncologist to qualify for chemoradiation.
- Pre-existing hepatic impairment: The screening for total bilirubin \> 1.5 times the upper limit of normal will be done by the oncologist to qualify for chemoradiation. The screening for \>2 times the upper limit of normal hepatotoxicity: Alkaline phosphatase (ALP) and Alanine aminotransferase (ALT) will be done by the oncologist to qualify for chemoradiation.The screening results for Aspartate aminotransferase (AST) must be \< 2 times the upper limit of normal if available in the medical records.
- Pre-existing Tourette's syndrome
- Seizure disorder
- Anorexia/bulimia in past two months
- Use of monoamine oxidase (MAO inhibitors) within 14 days
- Patients undergoing abrupt discontinuation of ethanol or sedatives (including benzodiazepines)
- Patients currently taking any of the study drugs
- Hypersensitivity to any tetracyclines
- Patients on anticoagulants (ie warfarin/heparin)
- Patients with INR \> 1.5.
- Patients being treated with concurrent cetuximab chemotherapy with radiation therapy.
- Patients currently receiving any tetracycline family antibiotic or within the previous past 14 days before chemoradiation.
- Previous radiation therapy for a cancer in the head and neck region.
- Patients with a history of cardiac disease, including angina and cardiac ischemia, left ventricular hypertrophy, myocardial infarction, and mitral valve prolapse.
- Patients taking antifungals, antiretrovirals, and macrolides that are strong CYP3A4 strong inhibitors including indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, and nefazodone.
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01219673
Start Date
March 1 2013
End Date
January 1 2014
Last Update
February 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030